Axsome Therapeutics earnings spark fresh look at the stock

Axsome Therapeutics (AXSM) shares are back in focus after the company reported second quarter 2026 results on 10 August. Revenue for the period and first half increased, while net losses also widened.

Following the earnings release, Axsome Therapeutics shares have eased over the past month, with a 30 day share price return of 7.1% and a 7 day share price return of 3.3%. However, the year to date share price return of 19.6% and 1 year total shareholder return of 92.3% still point to strong longer term momentum.

If Axsome Therapeutics has you thinking more broadly about high growth opportunities in healthcare, it can be useful to scan other potential leaders through our healthcare focused screeners such as 40 healthcare AI stocks

The recent pullback after Axsome Therapeutics' mixed revenue growth and wider losses leaves a key tension. Are you seeing a reset in sentiment, or a fair reflection of what the current fundamentals support based on today’s valuation?

Most Popular Narrative: 24.4% Undervalued

The most followed narrative currently values Axsome Therapeutics at $282.51 per share compared with the recent close of $213.67. That gap is at the core of the growth story analysts are modelling.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Want to see why this CNS portfolio supports such a premium fair value for Axsome Therapeutics? The narrative leans heavily on sharp revenue expansion, margin uplift, and a future earnings profile that assumes today’s losses flip into substantial profitability. Curious which specific ramp in sales and earnings has to materialise for $282.51 to make sense?

Result: Fair Value of $282.51 (UNDERVALUED)

However, Axsome Therapeutics still faces clear pressure points, including ongoing net losses of $191.6m and heavy reliance on Auvelity and Sunosi to support future expectations.

Another View on Axsome Therapeutics valuation

While the analyst fair value for Axsome Therapeutics points to the stock trading at a discount, the current P/S ratio of 14.4x tells a different story. It is higher than the US Pharmaceuticals industry at 5x and above the fair ratio of 17.4x that the market could move toward. This raises questions about how much valuation risk you are comfortable with at today’s price.

Next Steps

Does the Axsome Therapeutics story so far leave you feeling confident or cautious about the current price and potential rewards? Take a moment to look through the underlying drivers yourself, then weigh up the 3 key rewards

Looking for more investment ideas beyond Axsome Therapeutics?

If Axsome Therapeutics sharpened your thinking, do not stop here. Use the Simply Wall St Screener to spot fresh ideas that match your style and risk comfort.

• Target resilient income by reviewing companies in the 10 dividend fortresses that focus on higher yields with an emphasis on durability.
• Hunt for quality at a discount by scanning the 53 high quality undervalued stocks that highlight stocks combining solid fundamentals with compressed valuations.
• Protect your downside by checking the 80 resilient stocks with low risk scores that concentrate on businesses with more robust risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.